GT Biopharma is trading 10.79% down at $6.41 after opening-session selling on September 22, 2026.
- No new company-specific announcement dated September 22 was identified.
- Available coverage does not explicitly connect the decline to a catalyst.
- Investors may remain focused on the September 15 financing, which included convertible preferred stock, 100% warrant coverage, and a $6.10 conversion price; the source does not attribute today’s decline to that transaction.